相关临床试验
102
23 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1834
进行中（未招募）
13
12.8%
已完成
44
43.1%
No Longer Available
1
1.0%
尚未招募
10
9.8%
招募中
26
25.5%
暂停
1
1.0%
终止
4
3.9%
撤回
3
2.9%
暂无批准数据
- The NIH has awarded a first installment of $4.6 million, part of up to $12.8 million over three years, to a multi-university team modeling drug-hormone interactions in women. - Thirteen researchers from Michigan State, Rutgers, Emory, Tulane, and other institutions will build computational models integrating age and reproductive cycle stage into drug predictions. - The project targets metabolic drugs such as metformin, insulin, and GLP-1 agents, whose effects may vary with shifting female hormone levels. - All computer models and data will be freely available worldwide, with findings intended to inform NIH guidelines and national safety standards.
- A study of 11,071 UK Biobank participants found that high nighttime light exposure is linked to potentially harmful changes in heart structure and function. - Participants wearing wrist light sensors for seven days who exceeded three lux at night showed left ventricular wall thickening and reduced chamber space. - Cardiac MRI three years later also revealed reduced heart muscle flexibility, an early indicator of heart dysfunction, plus changes in the right ventricle and left atria. - Researchers and editorialists say reducing nighttime light exposure should be considered a preventive strategy, with darkness framed as essential to cardiovascular health.
- Tulane University is spearheading a $500 million initiative to convert the long-vacant Charity Hospital in New Orleans into a pioneering medical research facility. - The 1930s-era art deco building, shuttered after Hurricane Katrina in 2005, will become a downtown hub of biomedical innovation with construction starting this fall. - The completed hub, scheduled for 2029, will house labs for hundreds of researchers, space for biomedical startups, and classrooms for medical and public health programs. - Tulane leaders describe the project as the largest, most significant initiative in the university's history, aiming to spur medical advancements benefiting the entire Gulf South.
- Rice University bioengineer Omid Veiseh has secured a $2.2 million grant from the Bill and Melinda Gates Foundation to develop implantable cell factory platforms that deliver therapeutic antibodies continuously for two years or longer. - The innovative technology aims to address critical limitations of current monoclonal antibody treatments, which require frequent high-dose injections and create fluctuating drug levels that impact patient adherence and healthcare costs. - Two complementary strategies are being developed: hydrogel capsules for subcutaneous injection targeting seasonal malaria prophylaxis, and wireless miniaturized devices for continuous HIV-neutralizing antibody production over four years. - The project builds on successful preclinical studies that demonstrated stable, year-long in vivo delivery of HIV-neutralizing antibodies, with potential to transform global access to biologic therapies in resource-limited settings.
- ARMR Sciences will begin human trials of its fentanyl vaccine in early 2025 with 40 healthy adults at the Centre for Human Drug Research in the Netherlands. - The vaccine works by attaching a carrier protein to a fentanyl-like molecule to generate antibodies that prevent fentanyl from crossing the blood-brain barrier. - Preclinical studies in rats demonstrated the vaccine blocked 92 to 98 percent of fentanyl from entering the brain, with protection lasting 20 weeks. - The vaccine could offer up to a year of protection in humans and represents a paradigm shift from reactive overdose treatments to preventive intervention.
- Answer ALS has launched LADDIA, a groundbreaking AI-powered drug discovery collaboration with GATC Health, Pennington Biomedical Research Center, and Tulane University to accelerate ALS treatment development. - The initiative leverages the world's largest open-access ALS dataset through the Neuromine Data Portal and GATC Health's proprietary AI platform to identify druggable therapeutic targets. - Currently, there are no known viable treatments for ALS, making this AI-driven approach critical for identifying new therapeutic pathways for the neurodegenerative disease. - The collaboration will roll out in two phases, focusing first on building infrastructure and then activating collaborative projects to generate high-impact scientific outputs.
- New research published in the European Heart Journal shows that consuming coffee exclusively in the morning reduces premature death risk by 16% and cardiovascular death risk by 31% compared to non-coffee drinkers. - A separate study of over 47,500 women found that regular caffeinated coffee consumption increases the likelihood of healthy aging by 2-5% per cup, with optimal benefits at three cups daily. - The timing of coffee consumption appears crucial, as morning intake aligns with circadian rhythms and inflammatory marker patterns, while afternoon or evening consumption shows no significant health benefits. - Coffee's protective effects were specific to caffeinated coffee, with decaffeinated versions and tea showing no significant association with healthy aging outcomes.
- Researchers from UT Health San Antonio and Tulane University have developed a new drug candidate that effectively eliminates senescent "zombie cells" from the liver, showing potential for treating MASLD and liver cancer. - The drug targets BCL-xl and BCL-2 proteins to induce senescent cell death, demonstrating superior efficacy in reducing liver damage and cancer growth compared to existing senolytics, with fewer side effects. - The breakthrough discovery addresses a critical healthcare need in San Antonio, where MASLD prevalence is high due to elevated rates of obesity and diabetes in the community.
